Currently Viewing:
The American Journal of Managed Care August 2009
Outcomes of Patients Discharged From Pharmacy-Managed Cardiovascular Disease Management
Kari L. Olson, PharmD; Thomas Delate, PhD; Jon Rasmussen, PharmD; Tammy L. Humphries, PharmD; and John A. Merenich, MD; for the Clinical Pharmacy Cardiac Risk Service Study Group
Burden of Alzheimer's Disease and Association With Negative Health Outcomes
Daniel C. Malone, RPh, PhD; Trent P. McLaughlin, PhD; Peter M. Wahl, BA; Christopher Leibman, PharmD; H. Michael Arrighi, PhD; Mark J. Cziraky, PharmD; and Lisa M. Mucha, PhD
Distal Upper and Lower Limb Fractures Associated With Thiazolidinedione Use
Stephen G. Jones, MS; Soyal R. Momin, MS, MBA; Matthew W. Good, MD; Terence K. Shea, PharmD; and Kenneth Patric, MD
Cost Comparison of Peritoneal Dialysis Versus Hemodialysis in End-Stage Renal Disease
Ariel Berger, MPH; John Edelsberg, MD, MPH; Gary W. Inglese, RN, MBA; Samir K. Bhattacharyya, PhD; and Gerry Oster, PhD
Cost Evaluation of a Coordinated Care Management Intervention for Dementia
O. Kenrik Duru, MD, MSHS; Susan L. Ettner, PhD; Stefanie D. Vassar, MS; Joshua Chodosh, MD, MSPH; and Barbara G. Vickrey, MD, MPH
Can a Nationwide Media Campaign Affect Antibiotic Use?
Beatriz Hemo, MA; Naamah H. Shamir-Shtein, MA; Barbara G. Silverman, MD, MPH; Judith Tsamir, MA; Anthony D. Heymann, MB; Sharon Tsehori, MD, MHA; and Nurit L. Friedman, PhD
Cost Minimization of Medicare Part D Prescription Drug Plan Expenditures
Rajul A. Patel, PharmD, PhD; Helene Levens Lipton, PhD; Timothy W. Cutler, PharmD; Amanda R. Smith, MPH; Shirley M. Tsunoda, PharmD; and Marilyn R. Stebbins, PharmD
Currently Reading
Medicare Part D After 2 Years
Geoffrey F. Joyce, PhD; Dana P. Goldman, PhD; William B. Vogt, PhD; Eric Sun, PhD; and Anupam B. Jena, PhD
A Telephone-Based Intervention for Increasing the Use of Osteoporosis Medication: A Randomized Controlled Trial
Jill Waalen, MD, MPH; Amalia L. Bruning, PA; Mark Jason Peters, MD; and Eric M. Blau, MD

Medicare Part D After 2 Years

Geoffrey F. Joyce, PhD; Dana P. Goldman, PhD; William B. Vogt, PhD; Eric Sun, PhD; and Anupam B. Jena, PhD

Coverage under Part D is comparable to that under non–Part D plans with respect to key features likely to be important to Medicare beneficiaries.

Our analysis suggests that coverage under Part D is comparable to that under selected non–Part D plans with respect to key features likely to be important to Medicare beneficiaries—access to medications and out-of-pocket costs. However, the government should continue to monitor the competitiveness of the Part D market to ensure it meets the diverse needs of Medicare beneficiaries.

We thank Mark Totten, MS, for programming assistance; Meilinda Huang, BA, and Evie Spanos, BA, for research assistance; Taylor Dennen, PhD, for providing the data; and Chris Perrone, MPP, for helpful discussions.

Author Affiliations: From RAND Corporation, Santa Monica, CA (GFJ, DPG, ES, ABJ) and Pittsburgh, PA (WBV); and the University of Chicago (ES, ABJ), Chicago, IL.

Funding Source: This research was sponsored by the California Health-Care Foundation, the National Institute on Aging through its support of the RAND Roybal Center for Health Policy Simulation (grant P30AG024968), UnitedHealth Group, and the Bing Center for Health Economics. Drs Sun and Jena received fellowship funding from the National Institutes of Health through the Medical Scientist Training Program at the University of Chicago (grant 5 T32 GM07281). None of the sponsors had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Drs Joyce and Goldman had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Author Disclosure: The authors (GFJ, DPG, WBV, ES, ABJ) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.

Authorship Information: Concept and design (GFJ, DPG); acquisition of data (GFJ, DPG); analysis and interpretation of data (GFJ, DPG, WBV, ES, ABJ); drafting of the manuscript (GFJ, DPG, WBV, ES, ABJ); critical revision of the manuscript for important intellectual content (GFJ, DPG, WBV, ES, ABJ); statistical analysis (GFJ, WBV); provision of study materials or patients (GFJ); obtaining funding (GFJ, DPG); administrative, technical, or logistic support (GFJ); and supervision (GFJ, DPG).

Address correspondence to: Geoffrey F. Joyce, PhD, RAND Corporation, 1776 Main St, Santa Monica, CA 90407-2138. E-mail:

1. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
2. Poisal JA. Reporting of drug expenditures in the MCBS. Health Care Financ Rev. 2003;25(2):23-36.
3. Rice T, Desmond K, for The Henry J. Kaiser Family Foundation. Low-Income Subsidies for the Medicare Prescription Drug Benefit: The Impact of the Asset Test. April 2005. Publication 7304. Accessed January 8, 2008.
4. Cubanski J, Neuman P. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Aff (Millwood). 2007;26(1):w1-12.
5. Yin W, Basu A, Zhang JX, Rabbani A, Meltzer DO, Alexander GC. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 2008;148(3):169-177.
6. Lichtenberg FR, Sun SX. The impact of Medicare Part D on prescription drug use by the elderly. Health Aff (Millwood). 2007;26(6):1735-1744.
7. Winter J, Balza R, Caro F, et al. Medicare prescription drug coverage: consumer information and preferences. Proc Natl Acad Sci U S A. 2006;103(20):7929-7934.
8. Hsu J, Fung V, Price M, et al. Medicare beneficiaries’ knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA. 2008;299(16):1929-1936.
9. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA. 2008;299(16):1922-1928.
10. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349-2359.
11. Joyce GF, Goldman DP, Karaca-Mandic P, Zheng Y. Pharmacy benefit caps and the chronically ill. Health Aff (Millwood). 2007;26(5):1333-1344.
12. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-655.
13. Hoadley J, for The Health Policy Institute, Georgetown University; Hargrave E, for NORC at the University of Chicago; and Cubanski J, Neuman T, for The Henry J. Kaiser Family Foundation. The Medicare Part D Coverage Gap: Costs and Consequences in 2007. August 2008. Publication 7811. Accessed May 28, 2009.
14. Scott Morton FM. Prescription Drug Pricing and Negotiation: An Overview and Economic Perspectives for the Medicare Prescription Drug Benefit. Testimony for the Senate Finance Committee. January 11, 2007. Accessed May 28, 2009.
15. Congressional Budget Office. A Detailed Description of CBO’s Cost Estimate for the Medicare Prescription Drug Benefit. July 2004. Accessed May 28, 2009.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up